SL Science Holding shows weak fundamental quality (0/9 Piotroski, no moat) and a confirmed falling-knife downtrend (death cross, RSI 39, bearish MACD), and the engine's own asymmetry check models 0% upside even though a resistance-based price target implies 137% upside — a conflict the data does not resolve, keeping the stock flagged for exit.
Thesis pillars
- Weak Quality No Moat→Stable
- Confirmed Falling Knife Downtrend↑Improving
- Upside Estimate Conflict→Stable
- +1 more pillar — see the Why tab for full reasoning
SL Science Holding Limited (SLBT) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $3.00: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.3/10.
SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells,... Read more
Sell if holding. Multiple concerning factors at $3.00: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.3/10. Chart setup: Death cross but MACD improving, RSI 54. Score 4.3/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-09-04Recent Developments — SL Science Holding Limited
Latest news
- NEWS 12 Health Care Stocks Moving In Thursday's Pre-Market Session — benzinga Sep 3, 2026 neutral
- NEWS NetApp, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session — benzinga Sep 3, 2026 neutral
- NEWS Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket — benzinga Sep 3, 2026 positive
- NEWS SL Science Highlighted The Filing Of A New Drug Master File With The U.S. FDA Covering Exosomes Derived From Gamma Delta — benzinga Aug 27, 2026 positive
- NEWS SL Science Highlights New FDA Drug Master File For GDT Cell-Derived Exosomes — benzinga Aug 27, 2026 positive
Generated 2026-09-05T01:07:05Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Revenue shrinking — -7.6% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $3.00: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.3/10. Chart setup: Death cross but MACD improving, RSI 54. Prior stop was $2.68. Score 4.3/10, moderate confidence.
Take-profit target: $3.26 (+13.2% upside). Prior stop was $2.68. Stop-loss: $2.68.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.3/10; Weak growth.
SL Science Holding Limited trades at a P/E of N/A (forward N/A). TrendMatrix value score: 5.0/10. Verdict: Sell.
What does SL Science Holding Limited do?SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL...
SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.